Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Cardiac Toxicity in Recipients of Hematopoietic Stem Cell Transplant with Post Transplant Cyclophosphamide

Allison Gradone, Xia Bi, Satya Durugu, Boula Gattas, Alicia Bao, ArponaDev Nath, Joanne Filicko-O'Hara, Brenda Grande, Gina Mateja, William O'Hara, John Wagner, Dolores Grosso, Neal Flomenberg, Usama Gergis

Blood (2024) 144 (Supplement 1): 2176.

https://doi.org/10.1182/blood-2024-211954

Published: 2024

Journal Articles

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Justin M. Darrah, Indumathy Varadarajan, Amitkumar Mehta, Jennifer N. Saultz, Matthew McKinney, Monalisa Ghosh, Usama Gergis, Girish Bende, Siddha Kasar, Bradley Hupf, Sharon Chen, Leopold Sellner, Reem Karmali

Blood (2024) 144 (Supplement 1): 95.

https://doi.org/10.1182/blood-2024-194807

Published: 2024

Journal Articles

A Novel Chemo-Based Reduced Intensity Haploidentical Two-Step Allogeneic Hematopoietic Stem Cell Transplantation, Results of a Prospective Clinical Trial

Alicia Bao, Xia Bi, Allison Gradone, Boula Gattas, Arpona Dev Nath, Brenda Grande, Gina Mateja, Joanne Filicko-O'Hara, William O'Hara, John Wagner, Dolores Grosso, Neal Flomenberg, Usama Gergis

Blood (2024) 144 (Supplement 1): 4891.

https://doi.org/10.1182/blood-2024-211810

Published: 2024

Journal Articles

Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

Blood (2024) 144 (Supplement 1): 5092.

https://doi.org/10.1182/blood-2024-198455

Published: 2024

Journal Articles

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

Usama Gergis, Aaron Martin, Alex Vogel, Jeff Smith, Andreas Klein, Ran Reshef, Rajneesh Nath, Adam J. Olszewski, Alan List, Alex F. Herrera, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7175.

https://doi.org/10.1182/blood-2024-210499

Published: 2024

Journal Articles

Letermovir Prophylaxis Is Effective in Preventing CMV Reactivation and Is Associated with Decreased Non-Relapse Mortality in Two-Step Allogeneic Stem Cell Transplantation

Matthew J Tucker, Marc Yorker, Joanne Filicko-O'Hara, William O'Hara, Usama Gergis, Gina Keiffer, Xia Bi

Blood (2024) 144 (Supplement 1): 7320.

https://doi.org/10.1182/blood-2024-208745

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

TBI-Based Myeloablative Conditioning Two-Step Haploidentical Allogeneic Hematopoietic Stem Cell Transplant Yields Excellent Outcomes in Fit Patients with High-Risk Hematologic Malignancies, Results of a Prospective Trial

Boula Gattas, Xia Bi, Dolores Grosso, Alicia Bao, Allison Gradone, Brenda Grande, Gina Mateja, Arpona Dev Nath, Joanne Filicko-O'Hara, William O'Hara, John Wagner, Neal Flomenberg, Usama Gergis

Blood (2024) 144 (Supplement 1): 509.

https://doi.org/10.1182/blood-2024-211147

Published: 2024

Journal Articles

Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience

Xia Bi, Zoe Begun, Dolores A. Grosso, Margaret Kasner, Gina Keiffer, Joanne Filicko-O'Hara, William O'Hara, John L. Wagner, Lindsay Wilde, Neal Flomenberg, Zixuan Wang, Usama Gergis

Blood (2023) 142 (Supplement 1): 2847.

https://doi.org/10.1182/blood-2023-179931

Published: 2023

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Blood (2023) 142 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2023-177693

Published: 2023

Journal Articles

Low Disease Relapse and High Survival in Non-Myeloablative Two-Step Haploidentical Transplant, Results of a Prospective Trial

Xia Bi, Dolores A. Grosso, John L. Wagner, Joanne Filicko-O'Hara, William O'Hara, Neal Flomenberg, Usama Gergis

Blood (2023) 142 (Supplement 1): 4908.

https://doi.org/10.1182/blood-2023-178779

Published: 2023

Journal Articles

Outcome of Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide - a Single Center Experience

Yang Yang, Adam F. Binder, Xia Bi, Joanne Filicko-O'Hara, William O'Hara, Neal Flomenberg, Dolores A. Grosso, John L. Wagner, Arpona Dev Nath, Sikemi Ibikunle, Eliabeth Spitz, Usama Gergis

Blood (2023) 142 (Supplement 1): 7110.

https://doi.org/10.1182/blood-2023-173576

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Blood (2023) 142 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2023-174477

Published: 2023

Journal Articles

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Mohammad Alhomoud, Usama Gergis, Adrienne A. Phillips, Jingmei Hsu, Zhengming Chen, Alexandra Gomez-Arteaga, Tsiporah B. Shore, Joseph Scandura, Koen Van Besien, Sebastian A. Mayer

Blood (2022) 140 (Supplement 1): 7583–7584.

https://doi.org/10.1182/blood-2022-170097

Published: 2022

Journal Articles

Characterization of Real-World Chronic Graft-Versus-Host-Disease Patients Receiving Belumosudil

Usama Gergis, Charlie Nicholls, Praveen Potukuchi, Shaum M Kabadi, Deepika Verma, Nayan Patel, Olivia Li, Andrew Milgroom, Jeffrey R Skaar, Jonathan Ieyoub

Blood (2022) 140 (Supplement 1): 12869–12870.

https://doi.org/10.1182/blood-2022-167993

Published: 2022

Journal Articles

The Two-Step Approach to Haploidentical Transplant: Can Altering Timing in the Conditioning Regimen Increase Graft Versus Tumor Effects?

Dolores Grosso, Matthew Carabasi, Joanne Filicko-O'Hara, William O'Hara, Shannon Rudolph, John L. Wagner, Usama Gergis, Neal Flomenberg

Blood (2021) 138 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2021-146913

Published: 2021

Journal Articles

Chimeric Antigen Receptor T-Cell Therapy Treatment Patterns: A Retrospective Cohort Analysis of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in the US

Roxanna Seyedin, Julia Thornton Snider, Krithika Rajagopalan, Sally W Wade, Usama Gergis

Blood (2021) 138 (Supplement 1): 1424.

https://doi.org/10.1182/blood-2021-148067

Published: 2021

Journal Articles

High Survival in Patients with Myelofibrosis Undergoing a Two-Step Approach to Hematopoietic Stem Cell Transplantation (HSCT): Effects of Donor Source and Pre-HSCT Splenic Therapy on Outcomes

Shaik Rashid, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, William O'Hara, PharmD, Usama Gergis, MD, Neal Flomenberg, MD, Dolores Grosso, DNP, CRNP

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139630

Published: 2020

Journal Articles

Vaccination Response after Autologous Stem Cell Transplantation

Onder Alpdogan, MD, Jennifer Hong, MD, Thomas R. Klumpp, MD, Abdullateef O Abdulkareem, MD MPH, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Dolores Grosso, DNP, CRNP, Margaret Kasner, MDMSc, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Lindsay Wilde, MD, Pierluigi Porcu, MD, Usama Gergis, MD, John L. Wagner, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141269

Published: 2020

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134699

Published: 2020

NARROW

Cardiac Toxicity in Recipients of Hematopoietic Stem Cell Transplant with Post Transplant Cyclophosphamide

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

A Novel Chemo-Based Reduced Intensity Haploidentical Two-Step Allogeneic Hematopoietic Stem Cell Transplantation, Results of a Prospective Clinical Trial

Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

Letermovir Prophylaxis Is Effective in Preventing CMV Reactivation and Is Associated with Decreased Non-Relapse Mortality in Two-Step Allogeneic Stem Cell Transplantation

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

TBI-Based Myeloablative Conditioning Two-Step Haploidentical Allogeneic Hematopoietic Stem Cell Transplant Yields Excellent Outcomes in Fit Patients with High-Risk Hematologic Malignancies, Results of a Prospective Trial

Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Low Disease Relapse and High Survival in Non-Myeloablative Two-Step Haploidentical Transplant, Results of a Prospective Trial

Outcome of Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide - a Single Center Experience

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Characterization of Real-World Chronic Graft-Versus-Host-Disease Patients Receiving Belumosudil

The Two-Step Approach to Haploidentical Transplant: Can Altering Timing in the Conditioning Regimen Increase Graft Versus Tumor Effects?

Chimeric Antigen Receptor T-Cell Therapy Treatment Patterns: A Retrospective Cohort Analysis of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in the US

High Survival in Patients with Myelofibrosis Undergoing a Two-Step Approach to Hematopoietic Stem Cell Transplantation (HSCT): Effects of Donor Source and Pre-HSCT Splenic Therapy on Outcomes

Vaccination Response after Autologous Stem Cell Transplantation

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only